The Glitazones, Lessons so Far

  • Monika Shirodkar
  • Serge Jabbour

Keywords: Pioglitazone, Rosiglitazone, Giltazones, Diabetes, Thiazolidinediones, Insulin Resistance.


Insulin Resistance Glycemic Control Polycystic Ovary Syndrome Retinal Endothelial Cell Pioglitazone Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Adams M, Montague CT, Prins JB, et al. Activators of Peroxisome Proliferator-Activated Receptor gamma Have Depot-Specific Effects on Human Preadipocyte Differentiation. J Clin Invest. 1997; 100(12):3149–3153.CrossRefPubMedGoogle Scholar
  2. 2.
    Vidal-Puig AJ, Considine RV, Jimenez-Liñan M, et al. Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest. 1997;99(10): 2416–2422.CrossRefPubMedGoogle Scholar
  3. 3.
    Roden M, Price TB, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest. 1996;97:2859–2865.CrossRefPubMedGoogle Scholar
  4. 4.
    Oakes ND, Thalen PG, Jacinto SM, et al. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes. 2001;50:1158–1165.CrossRefPubMedGoogle Scholar
  5. 5.
    Iwata M, Haruta T, Usui I, et al. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator-activated receptor-gamma. Diabetes. 2001;50:1083–1092.CrossRefPubMedGoogle Scholar
  6. 6.
    Phillips SA, Ciaraldi TP, Kong AP, et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 2003;52(3): 667–674.CrossRefPubMedGoogle Scholar
  7. 7.
    Akazawa S, Sun F, Ito M, et al. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000;23:1067–1071.CrossRefPubMedGoogle Scholar
  8. 8.
    Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes. New Engl J Med. 1998;338(13): 867–872.CrossRefPubMedGoogle Scholar
  9. 9.
    Nolan JJ, Bernhard L, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994;331(18):1188–1193.CrossRefPubMedGoogle Scholar
  10. 10.
    Petersen KF, Krssak M, Inzucchi S, et al. Mechanism of troglitazone action in type 2 diabetes. Diabetes. 2000;49:827–831.CrossRefPubMedGoogle Scholar
  11. 11.
    Maggs DG, Buchanan TA, Burant CF, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998; 128(3):176–185.PubMedGoogle Scholar
  12. 12.
    Shimabukuro M, Zhou YT, Lee Y, et al. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem. 1998;273(6):3547–3550.CrossRefPubMedGoogle Scholar
  13. 13.
    Unger RH. Lipotoxic diseases. Annual Rev of Medicine 2002;53:319–336.CrossRefGoogle Scholar
  14. 14.
    Yang L, An HX, Deng XL, et al. Rosiglitazone reverses insulin secretion altered by chronic exposure to free fatty acid via IRS-2-associated phosphatidylinositol 3-kinase pathway. Acta Pharmacologica Sinica. 2003;24(5):429–434.PubMedGoogle Scholar
  15. 15.
    Finegood DT, McArthur MD, Kojwang D, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001;50(5):1021–1029.CrossRefPubMedGoogle Scholar
  16. 16.
    Buckingham RE, Al-Barazanji KA, Toseland CD, et al. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes. 1998;47(8): 1326–1334.CrossRefPubMedGoogle Scholar
  17. 17.
    Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care. 2000;23(11):1605–1611.CrossRefPubMedGoogle Scholar
  18. 18.
    Kipnes M S, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001;111(1): 10–17.CrossRefPubMedGoogle Scholar
  19. 19.
    Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther. 2000;22(12):1395–1409.CrossRefPubMedGoogle Scholar
  20. 20.
    Rubin C, Egan J, Schneider R. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes [abstract 0474]. Diabetes. 1999;48(suppl 1):A110.Google Scholar
  21. 21.
    Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24(2):308–315.CrossRefPubMedGoogle Scholar
  22. 22.
    Lebovitz LE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86(1):280–288.CrossRefPubMedGoogle Scholar
  23. 23.
    Wolffenbuttel BHR, Gomist R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med. 2000;17:40–47.CrossRefPubMedGoogle Scholar
  24. 24.
    Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of Metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283(13):1695–1702.CrossRefPubMedGoogle Scholar
  25. 25.
    Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24(7):1226–1232.CrossRefPubMedGoogle Scholar
  26. 26.
    Gerstein H, Yusuf S, Holman R, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose. Lancet 2006;368:1096–1105.CrossRefPubMedGoogle Scholar
  27. 27.
    Prescribing information for pioglitazone. Takeda Pharmaceuticals. February, 2000.Google Scholar
  28. 28.
    Aoyama E, Tsujiuchi H, Asahi S, et al. In vitro studies on the metabolic pathways of pioglitazone [abstract 418-P]. Diabetes. 2001;50(suppl 2):A105.CrossRefGoogle Scholar
  29. 29.
    Fonseca V, Valiquett TR, Huang SM, et al. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. J Clin Endocrinol Metab. 1998;83(9):3169–76.CrossRefPubMedGoogle Scholar
  30. 30.
    Prince MJ, Zagar AJ, Robertson KE. Effect of pioglitazone on HDL-C, a cardiovascular risk factor in type 2 diabetes [abstract 514-P]. Diabetes. 2001; 50(suppl 2):A128.Google Scholar
  31. 31.
    Dormany J, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study. Lancet. 2005;366:1279–1289.CrossRefGoogle Scholar
  32. 32.
    Li AC, Brown KK, Silvestre MJ, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000;106(4):523–531.CrossRefPubMedGoogle Scholar
  33. 33.
    Collins AR, Noh G, Hsueh WA, et al. PPARγ ligands attenuate angiotensin-II accelerated atherosclerosis in male low density receptor deficient (LDLR-/-) mice[abstract 292-PP]. Diabetes. 2001;50(suppl 2): A72–A73.Google Scholar
  34. 34.
    Yoshimoto T, Naruse M, Shizume H, et al. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis. 1999; 145:333–340.CrossRefPubMedGoogle Scholar
  35. 35.
    Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 1998;83(5):1818–1820.CrossRefPubMedGoogle Scholar
  36. 36.
    Koshiyama H, Shimono D, Kuwamura N, et al. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 2001;86(7):3452–3456.CrossRefPubMedGoogle Scholar
  37. 37.
    Choi SH, Choi DH, Ko YK, et al. Preventive effects of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. ADA 63rd Scientific Sessions 2003;82-OR.Google Scholar
  38. 38.
    Schneider RL, Shaffer SJ. Long-Term Echocardiographic Assessment in patients with type 2 diabetes mellitus treated with pioglitazone [abstract 504-P]. Diabetes. 2000;49(suppl 1):A124.Google Scholar
  39. 39.
    Sutton MSJ, Dole JF, Rappaport EB. Rosiglitazone does not adversely affect cardiac structure or function in patients with type 2 diabetes [abstract 0438]. Diabetes. 1999;48(suppl 1):A102.Google Scholar
  40. 40.
    Actos (pioglitazone hydrochloride) [package insert]. Lincolnshire, Ill: Takeda Pharmaceuticals America, Inc; 2000.Google Scholar
  41. 41.
    Walker AB, Chattington PD, Buckingham RE, et al. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes. 1999;48(7):1448–1453.CrossRefPubMedGoogle Scholar
  42. 42.
    Buchanan TA, Meehan WP, Jeng YY, et al. Blood pressure lowering by pioglitazone: evidence for a direct vascular effect. J Clin Invest. 1995;96:354–360.CrossRefPubMedGoogle Scholar
  43. 43.
    Yang T, Michele DE, Park J, et al. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol. 1999;277(6):F966–F973.PubMedGoogle Scholar
  44. 44.
    Guan YF, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int. 2001;60: 14–30.CrossRefPubMedGoogle Scholar
  45. 45.
    Asano T, Wakisaka M, Yoshinari M, et al. Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation. Biochim Biophys Acta. 2000;1497(1): 148–154.CrossRefPubMedGoogle Scholar
  46. 46.
    Nicholas SB, Kawano Y, Wakino S, et al. Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells. Hypertension. 2001;37(2 part 2):722–727.PubMedGoogle Scholar
  47. 47.
    Yoshimoto T, Naruse M, Nishikawa M, et al. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol. 1997;272(6):E989–E996.PubMedGoogle Scholar
  48. 48.
    Nakamura T, Ushiyama C, Shimada N, et al. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications. 2000;14(5):250–254.CrossRefPubMedGoogle Scholar
  49. 49.
    Murata T, Hata Y, Ishibashi T, et al. Response of experimental retinal neovascularization to thiazolidinediones. Arch Ophthalmol. 2001;119(5): 709–717.PubMedGoogle Scholar
  50. 50.
    Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38(4):1008–1017.PubMedGoogle Scholar
  51. Sanyal AJ, Contos MJ, Sargeant C, et al. A randomized controlled pilot study of pioglitazone and vitamin E versus vitamin E for nonalcoholic steatohepatitis (abstract). Hepatology 2002;382A.Google Scholar
  52. 52.
    Promrat K, Lutchman G, Kleiner DE, et al. Pilot study of pioglitazone in nonalcoholic steatohepatitis (abstract). Gastroenterology, 2003;124(4) (Suppl 1):A708.CrossRefGoogle Scholar
  53. 53.
    Ghazeeri G, Kutteh WH, Bryer-Ash M, et al. Effect of rosiglitazone on spontaneous and clomiphene-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003;79(3):562–566.CrossRefPubMedGoogle Scholar
  54. 54.
    Brettenthaler N, De Geyter C, Huber P, et al. Effect of Insulin Sensitizer Pioglitazone on Insulin resistance, Hyperadrongenism, and Ovulatory Dysfunction in Women with Polycystic Ovary Syndrome. J of Clin Endocrinol Metabolism. 2004; 89(8):3835–3840.CrossRefGoogle Scholar
  55. 55.
    Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med. 1998;338(13):916–917.CrossRefPubMedGoogle Scholar
  56. 56.
    Misbin, RI. Troglitazone-associated hepatic failure. Am J Med. 1999;130(4):330.Google Scholar
  57. 57.
    Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med. 2000;132(2):118–121.PubMedGoogle Scholar
  58. 58.
    Maeda K. Hepatocellular injury in a patient receiving pioglitazone. Ann Inten Med 2001;135(4):306.Google Scholar
  59. 59.
    Al-Salman J, Arjomand H, Kemp DG, et al. Hepatocellular injury in a patient receiving rosiglitazone: a case report. Ann Intern Med. 2000;132(2): 121–124.PubMedGoogle Scholar
  60. 60.
    Ravinuthala RS, Nori U. Rosiglitazone toxicity. Ann Intern Med. 2000;133(8):658.PubMedGoogle Scholar
  61. 61.
    Donnelly R, Gray S, Idris I. Rosiglitazone and ankle swelling: an acute dose-dependent effect on endothelial permeability [abstract 275-OR]. Diabetes. 2001;50(suppl 1):A68.Google Scholar
  62. 62.
    Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Pharmacotherapy 2002;22(7): 924–929.CrossRefPubMedGoogle Scholar
  63. 63.
    Gorson DM. Significant weight gain with rezulin therapy. Arch Intern Med. 1999;159:199.CrossRefGoogle Scholar
  64. 64.
    Thomas ML, Lloyd SJ. Pulmonary edema associated with rosiglitazone and troglitazone. Ann Pharmacother. 2001;35:123–124.CrossRefPubMedGoogle Scholar
  65. 65.
    Shimizu H, Tsuchiya T, Sato N, et al. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care. 1998;21:1470–1474.CrossRefPubMedGoogle Scholar
  66. 66.
    King AB, Armstrong D. Characteristics of the patients who gain weight while on pioglitazone treatment [abstract 481-P]. Diabetes. 2001;50(suppl 1): A120.Google Scholar
  67. 67.
    Prescribing information for rosiglitazone. SmithKline Beecham Pharmaceuticals. February 2001.Google Scholar
  68. 68.
    Young MM, Squassante L, Wemer J, et al. Troglitazone has no effect on red cell mass or other erythropoietic parameters. Eur J Clin Pharmacol. 1999;55:101–104.CrossRefPubMedGoogle Scholar
  69. 69.
    Dogterom P, Jonkman JHG, Vallance SE. Rosiglitazone: no effect on erythropoiesis or premature red cell destruction [abstract 0424]. Diabetes. 1999;48(suppl 1):A98.Google Scholar
  70. 70.
    Freed MI, Allen A, Jorkasky DK, et al. Systemic exposure to rosiglitazone is unaltered by food. Eur J Clin Pharmacol. 1999;55(1):53–56.CrossRefPubMedGoogle Scholar
  71. 71.
    Carey RA, Liu Y. Pioglitazone does not markedly alter oral contraceptive or hormone replacement therapy pharmacokinetics [abstract 405-P]. Diabetes. 2000;49(suppl 1):A100.Google Scholar
  72. 72.
    Inglis AML, Miller AK, Culkin KT, et al. Rosiglitazone, a PPARg agonist, does not alter the pharmacokinetics of oral contraceptives [abstract 0443]. Diabetes. 2000;48(suppl1):A103.Google Scholar
  73. 73.
    Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc 2003;78(9):1088–1091.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Monika Shirodkar
    • 1
  • Serge Jabbour
    • 2
  1. 1.Division of Endocrinology, Diabetes & Metabolic Diseases Department of MedicineThomas Jefferson University HospitalPhiladelphiaUSA
  2. 2.PhiladelphiaUSA

Personalised recommendations